All In Biotech

Drug Trial Radar · NCT06941870

Efanesoctocog Alfa Prophylaxis in Patients With Hemophilia A With Synovial Hypertrophy

Prospective Interventional Study of Effectiveness of Efanesoctocog Alfa Prophylaxis on Synovial Hypertrophy in Patients With Hemophilia A

Last checked: Nov 19, 2026Latest source record: Nov 9, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

35

Planned (sponsor's estimate)

Start

Sep 23, 2025

Primary completion

Oct 25, 2027

Study completion Oct 25, 2027

Sponsor

Lead sponsor
SanofiSanofi (SNY)
Sponsor type
Industry
First posted
Apr 24, 2025

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 4
Allocation
Non randomized
Model
Single group
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 12 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The objective of the study is to assess the improvement of synovial hypertrophy during the 12 months of efanesoctocog alfa prophylaxis once per week (QW) in joints with existing evidence of synovial hypertrophy in participants with hemophilia A. The study duration for each participant is approximately 12 months.

Conditions

  • Factor VIII Deficiency

Interventions

  • Efanesoctocog alfaDrug

    Pharmaceutical form:Lyophilized powder in a sterile vial that requires reconstitution with sterile water for injection (diluent)-Route of administration:Intravenous

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Proportion of joints with improvement in the Hemophilia Early Arthropathy Detection with Ultrasound (HEAD-US) synovitis domain scoreTime frame: From Baseline up to Week 52

Locations

19 sites in 5 countries. Site status is shown where the registry gives one.

  • Orthopedic Institute for Children- Site Number : 8400009

    Los Angeles, California · Completed

  • University of California Davis Medical Center-Site Number: 8400005

    Sacramento, California · Recruiting

  • Indiana Hemophilia and Thrombosis Center- Site Number : 8400006

    Indianapolis, Indiana · Recruiting

  • University of Iowa- Site Number : 8400004

    Iowa City, Iowa · Recruiting

  • The Ohio State University Wexner Medical Center - CarePoint East- Site Number : 8400001

    Columbus, Ohio · Completed

  • Oregon Health and Science University-Site Number: 8400002

    Portland, Oregon · Recruiting

  • Washington Center for Bleeding Disorders- Site Number : 8400008

    Seattle, Washington · Recruiting

  • Investigational Site Number : 0360001

    Murdoch, Western Australia, Australia · Completed

  • Investigational Site Number : 1240002

    Calgary, Alberta, Canada · Recruiting

  • Investigational Site Number : 1240001

    St. John's, Newfoundland and Labrador, Canada · Recruiting

  • Investigational Site Number : 1240003

    Hamilton, Ontario, Canada · Recruiting

  • Investigational Site Number : 1240004

    Hamilton, Ontario, Canada · Completed

  • Investigational Site Number : 3920002

    Hiroshima, Japan · Completed

  • Investigational Site Number : 3920001

    Saitama, Japan · Recruiting

  • Investigational Site Number : 3920004

    Tokyo, Japan · Completed

  • Investigational Site Number : 3920003

    Kawasaki, Kanagawa, Japan · Recruiting

  • Investigational Site Number: 1580003

    Kaohsiung City, Taiwan · Recruiting

  • Investigational Site Number: 1580001

    Taichung, Taiwan · Recruiting

  • Investigational Site Number: 1580002

    Taipei, Taiwan · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.